Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW, Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams
Clin Infect Dis. 2015 60 (12): 1860-3

PMID: 25722197 · PMCID: PMC4542662 · DOI:10.1093/cid/civ155

In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.

© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail:

MeSH Terms (15)

Antitubercular Agents Arylamine N-Acetyltransferase Benzoxazines Cytochrome P-450 CYP2B6 Female Genotype HIV Infections Humans Male Peru Pharmacogenetics Rifampin South Africa Tuberculosis Uganda

Connections (1)

This publication is referenced by other Labnodes entities: